In order to show the impact of HBP in melanoma cells, we use two strategies to increase HBP's flux: (1) treatment with glucosamine (GlcN), which bypass GFAT entering in the pathway as glucosamine-6-phosphate (the product of GFAT enzymatic activity), or (2) through over expression of GFAT. The gene discussed is GFPT1; the disease is melanoma.